title: Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis.
abstract: We analyzed the effects of monophosphoryl lipid A (MPL), a relatively nontoxic immunostimulant derived from bacterial endotoxin, on the depressed in vitro immune function of leukocytes derived from six patients undergoing continuous ambulatory peritoneal dialysis and who had histories of recurrent bacterial peritonitis. MPL was also tested for its capacity to stimulate the proliferation of peritoneal fibroblasts, as determined by [3H]thymidine incorporation. In vitro incubation of peritoneal lymphocytes and macrophages (PM phi) with increasing amounts of MPL, up to 5 micrograms/ml, resulted in a dose-dependent enhancement of gamma interferon and interleukin-2 production by peritoneal lymphocytes and interleukin-1 release by PM phi. In vitro incubation of PM phi with MPL also resulted in an increase of PM phi bacterial killing and membrane Fc receptor number, although no change in peritoneal fibroblast proliferation was seen with any of the MPL concentrations tested. These results suggest that the peritoneal leukocyte dysfunction observed in patients undergoing continuous ambulatory peritoneal dialysis and who have high rates of peritonitis may be alleviated, to some degree, by MPL, without directly inducing a potentially deleterious fibrotic lesion.
authors.affiliation: Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Carozzi
authors.forename: M
authors.initials: M
authors.lastname: Salit
authors.forename: A
authors.initials: A
authors.lastname: Cantaluppi
authors.forename: M G
authors.initials: MG
authors.lastname: Nasini
authors.forename: S
authors.initials: S
authors.lastname: Barocci
authors.forename: S
authors.initials: S
authors.lastname: Cantarella
authors.forename: S
authors.initials: S
authors.lastname: Lamperi
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001419:Bacteria / Q000276:immunology; D002455:Cell Division; D002478:Cells, Cultured; D005260:Female; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007375:Interleukin-1 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000166:cytology*; D011961:Receptors, Fc / Q000096:biosynthesis; D014511:Uremia / Q000276:immunology* / Q000628:therapy
chemical_list: D007375:Interleukin-1; D007376:Interleukin-2; D008050:Lipid A; D011961:Receptors, Fc; D007371:Interferon-gamma; C048436:monophosphoryl lipid A